Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15703) 15703
Newspaper Article (431) 431
Book Chapter (319) 319
Newsletter (162) 162
Book / eBook (70) 70
Report (33) 33
Magazine Article (31) 31
Dissertation (13) 13
Conference Proceeding (11) 11
Reference (10) 10
Web Resource (8) 8
Government Document (5) 5
Trade Publication Article (4) 4
Book Review (2) 2
Paper (2) 2
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (12331) 12331
humans (12186) 12186
life sciences & biomedicine (11225) 11225
digestive system diseases (6784) 6784
male (6475) 6475
female (6430) 6430
oncology (5529) 5529
middle aged (5213) 5213
biological and medical sciences (4439) 4439
medical sciences (4404) 4404
aged (4362) 4362
adult (3664) 3664
tumors (3565) 3565
neoplasms (3386) 3386
cancer (3308) 3308
animals (2853) 2853
gastroenterology & hepatology (2765) 2765
digestive system (2317) 2317
surgery (2137) 2137
chemotherapy (2121) 2121
colorectal cancer (2077) 2077
care and treatment (2042) 2042
treatment outcome (2024) 2024
research (1977) 1977
cell line, tumor (1877) 1877
hepatocellular carcinoma (1844) 1844
medicine (1780) 1780
pharmacology. drug treatments (1740) 1740
prognosis (1651) 1651
metastasis (1650) 1650
aged, 80 and over (1641) 1641
health aspects (1607) 1607
mice (1594) 1594
research article (1571) 1571
liver cancer (1549) 1549
risk factors (1490) 1490
gastroenterology. liver. pancreas. abdomen (1430) 1430
patients (1371) 1371
cancer therapies (1317) 1317
cell biology (1215) 1215
apoptosis (1214) 1214
retrospective studies (1214) 1214
mutation (1211) 1211
abridged index medicus (1201) 1201
analysis (1201) 1201
gene expression (1188) 1188
proteins (1173) 1173
liver neoplasms - pathology (1161) 1161
antineoplastic agents - therapeutic use (1123) 1123
science & technology - other topics (1096) 1096
medical prognosis (1071) 1071
multidisciplinary sciences (1059) 1059
carcinoma, hepatocellular - pathology (1050) 1050
medicine & public health (1050) 1050
liver neoplasms - drug therapy (1044) 1044
genetic aspects (1039) 1039
antineoplastic combined chemotherapy protocols - therapeutic use (1015) 1015
kinases (982) 982
review (956) 956
studies (892) 892
development and progression (890) 890
science (876) 876
drug therapy (854) 854
neoplasms. tumors. oncology. including cancer and carcinogens (835) 835
hepatoma (813) 813
colorectal neoplasms - pathology (808) 808
liver (791) 791
neoplasm staging (788) 788
signal transduction (764) 764
gastroenterology (757) 757
carcinoma, hepatocellular - drug therapy (753) 753
gene expression regulation, neoplastic (725) 725
medical research (724) 724
diagnosis (710) 710
follow-up studies (698) 698
antineoplastic agents (694) 694
cell proliferation (672) 672
pharmacology & pharmacy (662) 662
antineoplastic agents - pharmacology (658) 658
time factors (658) 658
immunohistochemistry (637) 637
combined modality therapy (632) 632
surgery. transplantations, organ and tissue grafts. graft diseases (630) 630
colorectal neoplasms - drug therapy (618) 618
surgery of the digestive system (618) 618
adolescent (612) 612
stomach. duodenum. small intestine. colon. rectum. anus (592) 592
liver neoplasms - metabolism (583) 583
apoptosis - drug effects (570) 570
carcinoma, hepatocellular - metabolism (569) 569
colorectal neoplasms - genetics (569) 569
prospective studies (561) 561
endoscopy (555) 555
liver neoplasms - genetics (545) 545
biomarkers (540) 540
metastases (538) 538
survival analysis (534) 534
carcinoma, hepatocellular - genetics (528) 528
cell proliferation - drug effects (526) 526
endocrine system diseases (519) 519
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (11) 11
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
Online Resources - Online (6) 6
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (5) 5
St. Michael's Hospital - Stacks (2) 2
Credit Valley Hospital - Reference (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Robarts - Stacks (1) 1
Scarborough Hospital - General (1) 1
St. Michael's Hospital - Circulation Desk (1) 1
Women's College Hospital - Online (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16585) 16585
French (91) 91
Japanese (68) 68
Portuguese (43) 43
Chinese (38) 38
Spanish (35) 35
German (31) 31
Polish (26) 26
Russian (26) 26
Italian (17) 17
Hungarian (9) 9
Korean (7) 7
Czech (4) 4
Dutch (4) 4
Norwegian (3) 3
Romanian (2) 2
Turkish (2) 2
Arabic (1) 1
Finnish (1) 1
Slovenian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Association of surgical treatment, systemic therapy, and survival in patients with abdominal visceral melanoma metastases, 1965-2014 relevance of surgical cure in the era of modern systemic therapy
by Deutsch, Gary B and Flaherty, Devin C and Kirchoff, Daniel D and Bailey, Mariel and Vitug, Sarah and Foshag, Leland J and Faries, Mark B and Bilchik, Anton J
JAMA surgery, ISSN 2168-6254, 07/2017, Volume 152, Issue 7, pp. 672 - 678
Life Sciences & Biomedicine | Surgery | Science & Technology | Adrenal Gland Neoplasms - surgery | Adrenal Gland Neoplasms - drug therapy | Gastrointestinal Neoplasms - secondary | Age Factors | Digestive System Neoplasms - secondary | Gastrointestinal Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Pancreatic Neoplasms - drug therapy | Pancreatic Neoplasms - secondary | Digestive System Neoplasms - drug therapy | Adrenal Gland Neoplasms - secondary | Adult | Female | Retrospective Studies | Liver Neoplasms - secondary | Splenic Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Pancreatic Neoplasms - surgery | Liver Neoplasms - drug therapy | Gastrointestinal Neoplasms - surgery | Liver Neoplasms - surgery | Survival Rate | Melanoma - secondary | Splenic Neoplasms - surgery | Metastasectomy | Melanoma - drug therapy | Nivolumab | Digestive System Neoplasms - surgery | Aged | Melanoma - surgery | Splenic Neoplasms - secondary
Journal Article
Details down arrow
2. Full Text Menopausal hormone therapy and cancer risk: An overestimated risk?
by Simin, Johanna and Tamimi, Rulla and Lagergren, Jesper and Adami, Hans-Olov and Brusselaers, Nele
European journal of cancer (1990), ISSN 0959-8049, 10/2017, Volume 84, pp. 60 - 68
Oestrogen replacement therapy | Genital neoplasms | Digestive system neoplasms | Menopause | Female | Hormone replacement therapy | Breast neoplasms | Neoplasms | Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Middle Aged | Progestins - adverse effects | Endometrial Neoplasms - chemically induced | Neoplasms - prevention & control | Neoplasms - diagnosis | Estrogens - adverse effects | Incidence | Protective Factors | Neoplasms - chemically induced | Time Factors | Drug Compounding | Adult | Registries | Breast Neoplasms - epidemiology | Digestive System Neoplasms - epidemiology | Drug Administration Schedule | Risk Assessment | Risk Factors | Digestive System Neoplasms - prevention & control | Endometrial Neoplasms - epidemiology | Sweden - epidemiology | Estrogen Replacement Therapy - adverse effects | Ovarian Neoplasms - epidemiology | Progestins - administration & dosage | Aged | Ovarian Neoplasms - chemically induced | Breast Neoplasms - chemically induced | Estrogens - administration & dosage | Neoplasms - epidemiology | Care and treatment | Health aspects | Risk factors | Cancer | Hormone therapy | Oncology, Experimental | Estrogen | Research | Therapy | Ovarian carcinoma | Invasiveness | Liver | Health risks | Population studies | Breast cancer | Ovarian cancer | Esophagus | Confidence intervals | Progestin | Colon | Endometrium | Tumors | Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
by Davis, Ian D and Martin, Andrew J and Stockler, Martin R and Begbie, Stephen and Chi, Kim N and Chowdhury, Simon and Coskinas, Xanthi and Frydenberg, Mark and Hague, Wendy E and Horvath, Lisa G and Joshua, Anthony M and Lawrence, Nicola J and Marx, Gavin and McCaffrey, John and McDermott, Ray and McJannett, Margaret and North, Scott A and Parnis, Francis and Parulekar, Wendy and Pook, David W and Reaume, M. Neil and Sandhu, Shahneen K and Tan, Alvin and Tan, T. Hsiang and Thomson, Alastair and Tu, Emily and Vera-Badillo, Francisco and Williams, Scott G and Yip, Sonia and Zhang, Alison Y and Zielinski, Robert R and Sweeney, Christopher J and Australian New Zealand Urogenital and ENZAMET Trial Investigators and ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group
The New England journal of medicine, ISSN 0028-4793, 07/2019, Volume 381, Issue 2, pp. 121 - 131
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Phenylthiohydantoin - adverse effects | Androgen Receptor Antagonists - therapeutic use | Digestive System Neoplasms - secondary | Follow-Up Studies | Phenylthiohydantoin - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bone Neoplasms - secondary | Male | Fatigue - chemically induced | Androgen Receptor Antagonists - adverse effects | Seizures - chemically induced | Digestive System Neoplasms - drug therapy | Bone Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Kaplan-Meier Estimate | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Phenylthiohydantoin - analogs & derivatives | Prostatic Neoplasms - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Aged | Adenocarcinoma - mortality | Medical research | Medical imaging | Prostate-specific antigen | Clinical trials | Metastasis | Cancer therapies | Survival | Patients | Metastases | Design | Testosterone | Androgens | Castration | Prostate cancer | Seizures
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents
by Bodo, Sahra and Colas, Chrystelle and Buhard, Olivier and Collura, Ada and Tinat, Julie and Lavoine, Noémie and Guilloux, Agathe and Chalastanis, Alexandra and Lafitte, Philippe and Coulet, Florence and Buisine, Marie-Pierre and Ilencikova, Denisa and Ruiz-Ponte, Clara and Kinzel, Miriam and Grandjouan, Sophie and Brems, Hilde and Lejeune, Sophie and Blanché, Hélène and Wang, Qing and Caron, Olivier and Cabaret, Odile and Svrcek, Magali and Vidaud, Dominique and Parfait, Béatrice and Verloes, Alain and Knappe, Ulrich J and Soubrier, Florent and Mortemousque, Isabelle and Leis, Alexander and Auclair-Perrossier, Jessie and Frébourg, Thierry and Fléjou, Jean-François and Entz-Werle, Natacha and Leclerc, Julie and Malka, David and Cohen-Haguenauer, Odile and Goldberg, Yael and Gerdes, Anne-Marie and Fedhila, Faten and Mathieu-Dramard, Michèle and Hamelin, Richard and Wafaa, Badre and Gauthier-Villars, Marion and Bourdeaut, Franck and Sheridan, Eamonn and Vasen, Hans and Brugières, Laurence and Wimmer, Katharina and Muleris, Martine and Duval, Alex and European Consortium “Care for CMMRD” and European Consortium Care CMMRD
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2015, Volume 149, Issue 4, pp. 1017 - 1029.e3
Gastroenterology and Hepatology | Tumor | Colon Cancer | Predisposition | Functional Tests | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | MutL Protein Homolog 1 | Predictive Value of Tests | Colorectal Neoplasms - genetics | Colorectal Neoplasms, Hereditary Nonpolyposis - pathology | Humans | Drug Resistance, Neoplasm | Male | Neoplastic Syndromes, Hereditary - metabolism | Colorectal Neoplasms - diagnosis | Young Adult | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Germ-Line Mutation | Mismatch Repair Endonuclease PMS2 | Neoplastic Syndromes, Hereditary - genetics | Caco-2 Cells | Lymphocytes - metabolism | Genetic Predisposition to Disease | Colorectal Neoplasms, Hereditary Nonpolyposis - drug therapy | Brain Neoplasms - diagnosis | HCT116 Cells | Brain Neoplasms - genetics | Neoplastic Syndromes, Hereditary - diagnosis | Heredity | MutS Homolog 2 Protein - genetics | Brain Neoplasms - drug therapy | Multiplex Polymerase Chain Reaction | Antineoplastic Agents, Alkylating - therapeutic use | Colorectal Neoplasms, Hereditary Nonpolyposis - metabolism | Phenotype | Adenosine Triphosphatases - genetics | Biomarkers, Tumor - genetics | Neoplastic Syndromes, Hereditary - drug therapy | Microsatellite Instability | Neoplastic Syndromes, Hereditary - pathology | Brain Neoplasms - pathology | DNA Repair Enzymes - genetics | Genetic Testing - methods | Brain Neoplasms - metabolism | Case-Control Studies | Transfection | Colorectal Neoplasms, Hereditary Nonpolyposis - diagnosis | Adult | Female | Nuclear Proteins - genetics | Colorectal Neoplasms - metabolism | Reproducibility of Results | Colorectal Neoplasms, Hereditary Nonpolyposis - genetics | DNA-Binding Proteins - genetics | Lymphocytes - drug effects | Adaptor Proteins, Signal Transducing - genetics | Colorectal Neoplasms - pathology | Methylation | Lymphomas | Diagnosis | Gene mutations | Lymphocytes | Leukemia | Colorectal cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer
by Kopetz, Scott and Desai, Jayesh and Chan, Emily and Hecht, Joel Randolph and O'Dwyer, Peter J and Maru, Dipen and Morris, Van and Janku, Filip and Dasari, Arvind and Chung, Woonbook and Issa, Jean-Pierre J and Gibbs, Peter and James, Brian and Powis, Garth and Nolop, Keith B and Bhattacharya, Suman and Saltz, Leonard
Journal of clinical oncology, ISSN 0732-183X, 12/2015, Volume 33, Issue 34, pp. 4032 - 4038
Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Skin Neoplasms - drug therapy | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Tissue Distribution | Carcinoma, Squamous Cell - mortality | Skin Neoplasms - mortality | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Colorectal Neoplasms - mortality | Survival Rate | Mutation - genetics | Sulfonamides - pharmacokinetics | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Pilot Projects | Carcinoma, Squamous Cell - drug therapy | Sulfonamides - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Skin Neoplasms - genetics | Skin Neoplasms - secondary | Carcinoma, Squamous Cell - secondary | Indoles - pharmacokinetics | Indoles - therapeutic use | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Cohort Studies | Index Medicus | Gic5 | ORIGINAL REPORTS | Gic7
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
by Misale, Sandra and Yaeger, Rona and Hobor, Sebastijan and Scala, Elisa and Janakiraman, Manickam and Liska, David and Valtorta, Emanuele and Schiavo, Roberta and Buscarino, Michela and Siravegna, Giulia and Bencardino, Katia and Cercek, Andrea and Chen, Chin-Tung and Veronese, Silvio and Zanon, Carlo and Sartore-Bianchi, Andrea and Gambacorta, Marcello and Gallicchio, Margherita and Vakiani, Efsevia and Boscaro, Valentina and Medico, Enzo and Weiser, Martin and Siena, Salvatore and Di Nicolantonio, Federica and Solit, David and Bardelli, Alberto
Nature (London), ISSN 0028-0836, 06/2012, Volume 486, Issue 7404, pp. 532 - 536
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Immunotherapy | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antineoplastic agents | Tumors | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | ErbB Receptors - antagonists & inhibitors | Antibodies, Monoclonal - pharmacology | Colorectal Neoplasms - genetics | Humans | Panitumumab | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Antibodies, Monoclonal - therapeutic use | Proto-Oncogene Proteins - genetics | Mutation - genetics | Promoter Regions, Genetic - genetics | Disease Progression | Antibodies, Monoclonal, Humanized | Drug Resistance, Neoplasm - genetics | Colorectal Neoplasms - drug therapy | Alleles | Cell Line, Tumor | Cetuximab | Colorectal Neoplasms - pathology | Drug Resistance, Neoplasm - drug effects | Genes, ras - genetics | Proteins | Cloning | Mutation | Kinases | Experiments | Cancer therapies | Mass spectrometry | Index Medicus | targeted therapy | KRAS | colorectal cancer | acquired resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
by Rudalska, Ramona and Dauch, Daniel and Longerich, Thomas and Mcjunkin, Katherine and Wuestefeld, Torsten and Kang, Tae-Won and Hohmeyer, Anja and Pesic, Marina and Leibold, Josef and von Thun, Anne and Schirmacher, Peter and Zuber, Johannes and Weiss, Karl-Heinz and Powers, Scott and Malek, Nisar P and Eilers, Martin and Sipos, Bence and Lowe, Scott W and Geffers, Robert and Laufer, Stefan and Zender, Lars
Nature medicine, ISSN 1078-8956, 10/2014, Volume 20, Issue 10, pp. 1138 - 1146
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Niacinamide - analogs & derivatives | RNA, Small Interfering - genetics | Mitogen-Activated Protein Kinase 14 - antagonists & inhibitors | Humans | Male | Liver Neoplasms, Experimental - metabolism | Carcinoma, Hepatocellular - drug therapy | Mitogen-Activated Protein Kinase 14 - metabolism | RNA Interference | Carcinoma, Hepatocellular - genetics | Female | Antineoplastic Agents - pharmacology | Liver Neoplasms, Experimental - genetics | Liver Neoplasms - genetics | Signal Transduction | Mice, Inbred C57BL | Liver Neoplasms - drug therapy | Mitogen-Activated Protein Kinase 14 - genetics | Activating Transcription Factor 2 - metabolism | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | MAP Kinase Signaling System - drug effects | Liver Neoplasms, Experimental - drug therapy | Liver Neoplasms - metabolism | Mice | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Niacinamide - pharmacology | Carcinoma, Hepatocellular - metabolism | Liver cancer | Research | Drug therapy | Drug resistance | Analysis | Biomarkers | Signal transduction | Protein expression | Pharmacology | Ribonucleic acid--RNA | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers
by El-Rayes, B.F and Zalupski, M and Bekai-Saab, T and Heilbrun, L.K and Hammad, N and Patel, B and Urba, S and Shields, A.F and Vaishampayan, U and Dawson, S and Almhanna, K and Smith, D and Philip, P.A
Annals of oncology, ISSN 0923-7534, 10/2010, Volume 21, Issue 10, pp. 1999 - 2004
bevacizumab | oxaliplatin | gastric cancer | docetaxel | Oxaliplatin | Gastric cancer | Docetaxel | Bevacizumab | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Esophagogastric Junction - drug effects | Humans | Middle Aged | Bone Neoplasms - secondary | Male | Stomach Neoplasms - pathology | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Peritoneal Neoplasms - drug therapy | Lung Neoplasms - secondary | Adult | Female | Bone Neoplasms - drug therapy | Liver Neoplasms - secondary | Peritoneal Neoplasms - secondary | Liver Neoplasms - drug therapy | Esophagogastric Junction - pathology | Survival Rate | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Taxoids - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Neoplasm Staging | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
by Holderfield, Matthew and Deuker, Marian M and McCormick, Frank and McMahon, Martin
Nature reviews. Cancer, ISSN 1474-175X, 2014, Volume 14, Issue 7, pp. 455 - 467
Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Humans | Melanoma - enzymology | Drug Resistance, Neoplasm | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Animals | Skin Neoplasms - enzymology | Melanoma - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Mutation | Proto-Oncogene Proteins B-raf - metabolism | Antimitotic agents | Gene mutations | Melanoma | Physiological aspects | Genetic aspects | Research | Antineoplastic agents | Drug therapy | Health aspects | Protein kinases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights